Roth Capital Research Analysts Raise Earnings Estimates for Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ)

Posted by Scott Moore on May 17th, 2024

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) – Analysts at Roth Capital raised their Q2 2024 earnings per share (EPS) estimates for shares of Creative Medical Technology in a report released on Monday, May 13th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($0.84) for the quarter, up from their previous forecast of ($1.16). The consensus estimate for Creative Medical Technology’s current full-year earnings is ($4.68) per share. Roth Capital also issued estimates for Creative Medical Technology’s Q3 2024 earnings at ($0.85) EPS, Q4 2024 earnings at ($0.87) EPS, FY2024 earnings at ($3.29) EPS and FY2025 earnings at ($2.58) EPS.

Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.08).

Creative Medical Technology Stock Performance

CELZ stock opened at $4.34 on Wednesday. The firm has a market cap of $5.86 million, a P/E ratio of -1.16 and a beta of 2.22. The firm’s fifty day moving average is $5.10 and its 200 day moving average is $4.65. Creative Medical Technology has a 52 week low of $3.93 and a 52 week high of $10.28.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Creative Medical Technology stock. Aaron Wealth Advisors LLC purchased a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 16,400 shares of the company’s stock, valued at approximately $85,000. Aaron Wealth Advisors LLC owned about 1.21% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is currently owned by institutional investors.

Creative Medical Technology Company Profile

(Get Free Report)

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.